Exhibit 99.1 Avadel Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2024 Financial Results -- Generated $41.5 million in net revenue from sales of LUMRYZ™ -- -- More than 1,900 patients on LUMRYZ as of June 30 -- -- First patient dosed in Phase 3 trial evaluating LUMRYZ in idiopathic hypersomnia -- -- FDA target action date of September 7, 2024 for sNDA for LUMRYZ in pediatric narcolepsy -- -- Management to host a conference call today at 8:30 a.m. ET -- DUBLIN, Ireland, August 8, 2024 ...

DUBLIN, June 27, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024. “We are proud to be included in the widely tracked Russ ...

DUBLIN, June 27, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024. “We are proud to be included in the widely tracked Russ ...

– 11 accepted abstracts, including new data reiterating satisfaction, preference and clinical benefit of LUMRYZ – – Presentations highlight Avadel’s continued commitment to address gaps in narcolepsy care – DUBLIN, May 22, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today it will present 11 posters, and one oral presentation, supporting the use of LUMRYZ as a narcolepsy treatment option at SLEEP 2024, the 38th ...

DUBLIN, Ireland, May 21, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today the appointment of Naseem Amin, M.D. to its board of directors, effective May 17, 2024. Dr. Amin, a highly successful executive who brings global industry and leadership experience to Avadel, currently serves as Chief Executive Officer of Orphalan SA. "On behalf of the entire Avadel team, we are excited to welcome Dr. Am ...

DUBLIN, Ireland, May 21, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today the appointment of Naseem Amin, M.D. to its board of directors, effective May 17, 2024. Dr. Amin, a highly successful executive who brings global industry and leadership experience to Avadel, currently serves as Chief Executive Officer of Orphalan SA. “On behalf of the entire Avadel team, we are excited to welcome Dr. A ...

Avadel Pharmaceuticals plc (NASDAQ:AVDL) Q1 2024 Earnings Conference Call May 8, 2024 8:30 AM ET Company Participants Austin Murtagh - Director at Stern Investor Relations Gregory Divis - CEO Richard Kim - Chief Commercial Officer Thomas McHugh - CFO Conference Call Participants Andrew Tsai - Jefferies François Brisebois - Oppenheimer Ami Fadia - Needham & Company David Amsellem - Piper Sanger Marc Goodman - Leerink Partners Ashwani Verma - UBS Oren Livnat - H.C. Wainwright Chase Knickerbocker - Craig Hallu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— Title of each class Trading Symbol(s) Name of each exchange on which registered Ordinary Shares, nominal value $0.01 per share AVDL The Nasdaq Global Market FORM 10-Q ——————— ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period ...

Revenue and Sales Performance - Generated $27.2 million in net revenue from sales of LUMRYZ for the quarter ended March 31, 2024[5] - More than 1,700 patients initiated therapy with LUMRYZ, representing an increase of over 70% from December 31, 2023[3] - Over 2,800 patients enrolled in Avadel's RYZUP patient support services, an increase of approximately 50% since December 31, 2023[3] Expenses and Financial Performance - R&D expenses decreased to $3.1 million for the quarter, down from $3.8 million in the same period in 2023[5] - SG&A expenses increased to $48.6 million, compared to $24.5 million for the same period in 2023, driven by higher commercial launch costs[5] - Net loss for the quarter was $27.3 million, or ($0.30) per diluted share, compared to a net loss of $30.8 million, or ($0.48) per diluted share, for the same period in 2023[6] - Net loss for the three months ended March 31, 2024, was $27,342,000, an improvement from a net loss of $30,784,000 for the same period in 2023, representing a reduction of 7.93%[27] - The company reported a significant increase in share-based compensation expense to $5,389,000 for the three months ended March 31, 2024, compared to $1,522,000 for the same period in 2023[27] Cash and Assets - Cash, cash equivalents, and marketable securities totaled $88.8 million as of March 31, 2024[6] - Cash and cash equivalents rose to $35,794,000 at March 31, 2024, up from $31,167,000 at December 31, 2023, marking an increase of 14.99%[26] - Total current assets increased to $136,035,000 as of March 31, 2024, compared to $134,202,000 at December 31, 2023, reflecting a growth of 1.36%[23] Liabilities and Equity - Total liabilities increased to $89,515,000 as of March 31, 2024, compared to $76,959,000 at December 31, 2023, indicating a rise of 16.31%[24] - Total shareholders' equity decreased to $78,384,000 as of March 31, 2024, down from $87,739,000 at December 31, 2023, reflecting a decline of 10.66%[25] Market and Regulatory Developments - The FDA accepted the sNDA for LUMRYZ for pediatric narcolepsy, with a target action date of September 7, 2024[4] - The company is on track to enroll the first patient in a Phase 3 pivotal trial for idiopathic hypersomnia in the second half of 2024[4] Cash Flow and Financing Activities - Proceeds from sales of marketable securities amounted to $119,066,000 for the three months ended March 31, 2024, significantly higher than $15,295,000 for the same period in 2023[27] - Net cash used in operating activities was $29,704,000 for the three months ended March 31, 2024, slightly better than $30,233,000 for the same period in 2023, showing a decrease of 1.75%[27] - Cash flows from financing activities provided $13,190,000 for the three months ended March 31, 2024, compared to $34,442,000 for the same period in 2023, showing a decrease of 61.73%[27] Operating Lease and Other Liabilities - The current portion of operating lease liability increased to $953,000 as of March 31, 2024, compared to $934,000 at December 31, 2023, indicating a rise of 2.04%[24]

DUBLIN, Ireland, May 01, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, May 8, 2024, to provide a corporate update and discuss the Company's financial results for the first quarter ended March 31, 2024. To access the conference call, investors are invited to dial +1 (800) 715-9871 (U.S. and Canada) or +1 (646) ...